Clinical Trial: WT1 Peptid Vaccination in Carcinomas

Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Carcinomas

Brief Summary: In this trial HLA-A2+ patients with WT1 expressing carcinomas are vaccinated with a peptide from the leukemia associated antigen WT1 together with immunological adjuvants KLH as T-helper protein and GM-CSF

Detailed Summary:
Sponsor: Charite University, Berlin, Germany

Current Primary Outcome: Clinical efficacy

Original Primary Outcome: Same as current

Current Secondary Outcome:

• Immune response
• Safety

Original Secondary Outcome: Same as current

Information By: Charite University, Berlin, Germany

Dates:
Date Received: September 8, 2005
Date Started: April 2004
Date Completion:
Last Updated: February 13, 2006
Last Verified: September 2005